Disc Medicine Q2 loss bigger than expected as costs increase
Overview
Disc Medicine Q2 net loss of $55.2 mln missed analyst expectations
EPS for Q2 missed estimates, reflecting higher operating expenses
Company on track to submit NDA for bitopertin in EPP in Oct 2025
Outlook
Disc Medicine ends Q2 with $650 mln in cash, expected to fund operations into 2028
Result Drivers
CLINICAL TRIAL PROGRESSION - Increased R&D expenses driven by progression of bitopertin's clinical studies and DISC-0974 program-
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | Miss | -$55.25 mln | -$39.20 mln (8 Analysts) |
Q2 EPS | Miss | -$1.58 | -$1.16 (12 Analysts) |
Q2 Operating Income | Miss | -$61.41 mln | -$41.40 mln (8 Analysts) |
Q2 Operating Expenses |
| $61.41 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Disc Medicine Inc is $89.50, about 34.1% above its August 6 closing price of $59.00
Press Release: ID:nGNX82pT3H
